Table 4. PCR positivity for different real-time PCR assays.
| Clinical Form | Total number of biopsies | sodA(%) positivity | 16S (%) positivity | RLEP (%) positivity | 85B (%) positivity |
| BB | 5 | 4 (80) | 5 (100) | 5 (100) | 5 (100) |
| BL | 5 | 5 (100) | 5 (100) | 5 (100) | 5 (100) |
| LL | 11 | 11 (100) | 11 (100) | 11 (100) | 10 (90.9) |
| BT | 11[a] | 2 (18.2) | 2 (18.2) | 6 (54.5) | 4 (36.4) |
| I | 12[b] | 0 | 1 (8.3) | 9 (75) | 2 (16.7) |
| NP/TT | 3 | 0 | 0 | 2 (66.7) | 0 |
| Skin from healthy donor | 5 | 0 | 0 | 0 | 0 |
| Other dermatological diseases | 10 | 0 | 0 | 4 | 0 |
[a],[b]
1 BT (borderline tuberculoid) and 2 I (indeterminate) patients were initially classified as controls but confirmation of leprosy was done only after databank search (5–10 years after biopsy collection). Then, biopsies were reanalyzed histologically and also reclassified as patients according to R&J classification.